Literature DB >> 12107545

The role of mechanical devices in treating female sexual dysfunction and enhancing the female sexual response.

Kevin L Billups1.   

Abstract

Female sexual dysfunction (FSD) is a common medical problem estimated to affect about 40 million American women. In 1998, the American Foundation of Urologic Disease (AFUD) Consensus Panel classified FSD into four different categories: sexual desire disorder, sexual arousal disorder, orgasmic disorder, and sexual pain disorder. This article will focus on the role of mechanical devices to treat sexual arousal and orgasm disorders and to enhance the female sexual response. Mechanical devices may work through vibratory stimulation or by causing clitoral vascular engorgement using a vacuum system. While a number of vibratory stimulating devices are available, only one U.S. Food and Drug Administration cleared-to-market device is available by prescription to treat FSD, the Eros Therapy device (UroMetrics, Inc., St. Paul, Minn., USA). The Eros Therapy is a small, battery-powered device used to gently apply direct vacuum over the clitoris causing the clitoral erectile chambers and labia to fill with blood. This article will review the rationale and benefits of using mechanical devices to treat FSD.

Entities:  

Mesh:

Year:  2002        PMID: 12107545     DOI: 10.1007/s00345-002-0269-0

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  5 in total

Review 1.  Female Sexual Dysfunction: Is It a Treatable Disease?

Authors:  Justin Houman; Tom Feng; Karyn S Eilber; Jennifer T Anger
Journal:  Curr Urol Rep       Date:  2016-04       Impact factor: 3.092

2.  An international Urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for the assessment of sexual health of women with pelvic floor dysfunction.

Authors:  Rebecca G Rogers; Rachel N Pauls; Ranee Thakar; Melanie Morin; Annette Kuhn; Eckhard Petri; Brigitte Fatton; Kristene Whitmore; Sheryl A Kingsberg; Joseph Lee
Journal:  Int Urogynecol J       Date:  2018-03-26       Impact factor: 2.894

Review 3.  A biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review.

Authors:  Holly N Thomas; Rebecca C Thurston
Journal:  Maturitas       Date:  2016-02-21       Impact factor: 4.342

Review 4.  Female sexual dysfunction: state of the art.

Authors:  Aristotelis G Anastasiadis; Laurent Salomon; Mohamed A Ghafar; Martin Burchardt; Ridwan Shabsigh
Journal:  Curr Urol Rep       Date:  2002-12       Impact factor: 3.092

5.  Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.

Authors:  C Derzko; S Elliott; W Lam
Journal:  Curr Oncol       Date:  2007-12       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.